Consensus Mirum Pharmaceuticals, Inc.

Equities

MIRM

US6047491013

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
24.02 ^USD	-1.64%		+0.71%	-18.63%

Apr. 17	Stifel Initiates Mirum Pharmaceuticals With Buy Rating, $48 Price Target	MT
Apr. 02	Mirum Pharmaceuticals, Inc. receives Positive Reimbursement Recommendation for Livmarli (Maralixibat Oral Solution) by Canada?S Cadth for Patients with Cholestatic Pruritus in Alagille Syndrome	CI

Evolution of the average Target Price on Mirum Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

8e84e97178569ee2d14064e66ed641e.XqgWrRe5pDKGS10fo-ZF_EHKNihWWuN7JfKYFVW0V-c.GNx_5VKO9HjPIzt-6LIzqCmOABAMNasSRpfHUjTFYIgV8XnVdendVckjaQ~cf85a86eff2aa928350e339bbf2199ff

Analyst Recommendations on Mirum Pharmaceuticals, Inc.

Stifel Initiates Mirum Pharmaceuticals With Buy Rating, $48 Price Target	Apr. 17	MT
JMP Securities Raises Price Target on Mirum Pharmaceuticals to $72 From $69, Maintains Market Outperform Rating	Mar. 14	MT
HC Wainwright Adjusts Mirum Pharmaceuticals Price Target to $58 From $45, Maintain Buy Rating	Mar. 14	MT
Cantor Fitzgerald Adjusts Price Target on Mirum Pharmaceuticals to $40 From $35, Maintains Overweight Rating	Mar. 04	MT
Raymond James Cuts Price Target on Mirum Pharmaceuticals to $64 From $78, Keeps Strong Buy Rating	Dec. 19	MT
Morgan Stanley Starts Mirum Pharmaceuticals With Overweight Rating, $60 Price Target	Nov. 13	MT
Cantor Fitzgerald Initiates Mirum Pharmaceuticals With Overweight Rating, Price Target is $50	23-10-24	MT
Raymond James Cuts Price Target on Mirum Pharmaceuticals to $77 From $84, Maintains Strong Buy Rating	23-10-18	MT
JMP Securities Initiates Mirum Pharmaceuticals With Market Outperform Rating, Price Target is $70	23-09-20	MT
Raymond James Raises Mirum Pharmaceuticals Price Target to $84 From $79, Maintains Strong Buy Rating	23-08-21	MT
Raymond James Adjusts Price Target on Mirum Pharmaceuticals to $79 From $82, Maintains Strong Buy Rating	23-08-04	MT
HC Wainwright Adjusts Mirum Pharmaceuticals Price Target to $63 From $61, Maintains Buy Rating	23-07-18	MT
Raymond James Adjusts Price Target on Mirum Pharmaceuticals to $82 From $81, Maintains Strong Buy Rating	23-07-18	MT
Raymond James Trims Price Target on Mirum Pharmaceuticals to $81 From $83, Maintains Strong Buy Rating	23-04-13	MT
Raymond James Adjusts Price Target on Mirum Pharmaceuticals to $83 From $84, Keeps Strong Buy Rating	23-03-09	MT
HC Wainwright Adjusts Mirum Pharmaceuticals Price Target to $61 From $69, Maintains Buy Rating	23-02-15	MT
Raymond James Adjusts Price Target on Mirum Pharmaceuticals to $84 From $88, Maintains Strong Buy Rating	23-01-10	MT
SVB Securities Adjusts Price Target on Mirum Pharmaceuticals to $39 From $50, Maintains Outperform Rating	23-01-10	MT
SVB Securities Adjusts Price Target on Mirum Pharmaceuticals to $50 From $49, Maintains Outperform Rating	22-12-14	MT
Citigroup Adjusts Price Target on Mirum Pharmaceuticals to $34 From $38, Maintains Buy Rating	22-11-10	MT
Raymond James Raises Mirum Pharmaceuticals' Price Target to $88 From $75, Keeps Strong Buy Rating	22-10-25	MT
HC Wainwright Adjusts Mirum Pharmaceuticals' Price Target to $68 From $63, Maintains Buy Rating	22-10-25	MT
Citigroup Starts Mirum Pharmaceuticals at Buy With $38 Price Target	22-09-01	MT
SVB Securities Adjusts Mirum Pharmaceuticals' Price Target to $52 From $50, Keeps Outperform Rating	22-05-24	MT
HC Wainwright Adjusts Price Target for Mirum Pharmaceuticals to $69 From $64, Maintains Buy Rating	22-05-23	MT